Paper Details

  1. Home
  2. Paper Details

Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro.

Author: AltieriPaola, BallestreroAlberto, BarsottiAntonio, BrunelliClaudio, FabbiPatrizia, GaribaldiSilvano, GhigliottiGiorgio, MancaValeria, NastiSabina, PatroneFranco, RossettinPierfranco, SpallarossaPaolo

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Doxorubicin is a chemotherapy drug that can damage the heart. This study found that carvedilol, a drug that blocks the effects of adrenaline and also has antioxidant properties, protects heart cells from damage caused by doxorubicin. Atenolol, a beta-blocker without antioxidant properties, did not offer protection.
Paper Details　
Original Abstract of the Article :
The clinical use of doxorubicin, a highly active anticancer drug, is limited by its severe cardiotoxic side effects. Increased oxidative stress and apoptosis have been implicated in the cardiotoxicity of doxorubicin. Carvedilol is an adrenergic blocking agent with potent anti-oxidant activity. In th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/15380674

データ提供：米国国立医学図書館（NLM）

Carvedilol: A Camel's Insight into Doxorubicin Cardiotoxicity

This research explores the potential protective effects of carvedilol, an adrenergic blocking agent with antioxidant activity, against the cardiotoxic side effects of doxorubicin, a widely used anticancer drug. The study found that carvedilol effectively attenuated the generation of free radicals and apoptosis in cultured cardiac muscle cells exposed to doxorubicin, while atenolol, a beta-blocker without antioxidant activity, had no such protective effects. These findings suggest that carvedilol's antioxidant properties may offer a promising strategy for mitigating the heart damage associated with doxorubicin treatment.

The Camel's Perspective: A Shield Against Cardiotoxicity

This research delves into the potential of carvedilol to act as a shield against the cardiotoxic effects of doxorubicin. By demonstrating its ability to combat free radical generation and apoptosis, the study offers a glimmer of hope for patients undergoing doxorubicin therapy. The results highlight the importance of understanding the complex interactions between drugs and cellular mechanisms, paving the way for developing safer and more effective cancer treatments.

The Camel's Perspective: A Shield Against Cardiotoxicity

This research highlights the importance of considering the potential side effects of medications, especially those with a narrow therapeutic window. It underscores the need for developing strategies to mitigate these side effects and improve patient outcomes. It's like the desert, where finding ways to protect oneself from the harsh elements is crucial for survival.

Dr.Camel's Conclusion

This research demonstrates the potential of carvedilol to protect against doxorubicin-induced cardiotoxicity. Its antioxidant properties suggest that carvedilol may offer a valuable strategy for mitigating heart damage in patients undergoing cancer treatment.
Date :
  1. Date Completed 2005-03-01
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

15380674

DOI: Digital Object Identifier

S0022282804001658

Related Literature

Article Analysis
・Side Effects of carvedilol
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.